EUVIMEDEUVIMED entdecken
Crossref

Prognostic significance of Albumin–Bilirubin score changes in patients treated with systemic therapy for recurrent hepatocellular carcinoma after liver resection

Yoh Asahi, Tatsuhiko Kakisaka, Tatsuya Orimo, Shingo Shimada, Akihisa Nagatsu, Takeshi Aiyama, Sunao Fujiyoshi, Yuzuru Sakamoto, Yuki Fujii, Yuichi Yoshida, Shunsuke Shichi, Ken Imaizumi und 1 weitere

Surgery Today · 2025

DOI: 10.1007/s00595-025-03217-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Surgery Today, 2025. Verfasst von Yoh Asahi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Kita-ku, Kita 14, Nishi 5, Sapporo, 060-8648, Hokkaido,…. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Neoplasm Recurrence, Local, Hepatectomy. Die Arbeit nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To clarify the characteristics of patients who received systemic therapy for recurrent hepatocellular carcinoma after liver resection and evaluate the associated prognostic factors. METHODS: We retrospectively analyzed data from 177 hepatocellular carcinoma patients with recurrence after liver resection; 79 received tyrosine kinase inhibitors or immune checkpoint inhibitors. Prognostic factors were analyzed in the patients who received systemic therapy. RESULTS: The median survival time after the initiation of systemic therapy was 23.3 months among the patients who received such therapy. These patients had more advanced disease at recurrence than those who did not receive systemic therapy. In the systemic therapy group, a deterioration of liver function relative to the preoperative status, expressed as the change in the albumin-bilirubin score (≥ 0.469 vs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularNeoplasm Recurrence, LocalHepatectomyBilirubinProtein Kinase InhibitorsImmune Checkpoint InhibitorsSerum AlbuminHumansPrognosisRetrospective StudiesFemaleMaleMiddle AgedAgedSurvival RateTreatment OutcomeTime FactorsSerum Albumin, Human

Stichwörter der Autor:innen

Hepatocellular carcinomaImmune checkpoint inhibitorLiver resectionRecurrenceTyrosine kinase inhibitor

Substanzen

BilirubinProtein Kinase InhibitorsImmune Checkpoint InhibitorsSerum Albuminalbumin-bilirubin complexSerum Albumin, Human

Autor:innen und Institutionen

  • Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Kita-ku, Kita 14, Nishi 5, Sapporo, 060-8648, Hokkaido, Japan.
  • Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Kita-ku, Kita 14, Nishi 5, Sapporo, 060-8648, Hokkaido, Japan. kakisaka@k2.dion.ne.jp.
  • Department of Biostatistics, Graduate School of Medicine, Hokkaido University, Kita-ku, Kita 14, Nishi 5, Sapporo, 060-8648, Hokkaido, Japan.

Zitieren

APA

Asahi, Y., Kakisaka, T., Orimo, T., Shimada, S., Nagatsu, A., Aiyama, T., Fujiyoshi, S., Sakamoto, Y., Fujii, Y., Yoshida, Y., Shichi, S., Imaizumi, K., & Taketomi, A. (2025). Prognostic significance of Albumin–Bilirubin score changes in patients treated with systemic therapy for recurrent hepatocellular carcinoma after liver resection. Surgery Today. https://doi.org/10.1007/s00595-025-03217-5

Vancouver

Asahi Y, Kakisaka T, Orimo T, Shimada S, Nagatsu A, Aiyama T, et al. Prognostic significance of Albumin–Bilirubin score changes in patients treated with systemic therapy for recurrent hepatocellular carcinoma after liver resection. Surgery Today. 2025. doi:10.1007/s00595-025-03217-5

BibTeX
@article{Asahi2025,
  author = {Asahi, Yoh and Kakisaka, Tatsuhiko and Orimo, Tatsuya and Shimada, Shingo and Nagatsu, Akihisa and Aiyama, Takeshi and Fujiyoshi, Sunao and Sakamoto, Yuzuru and Fujii, Yuki and Yoshida, Yuichi and Shichi, Shunsuke and Imaizumi, Ken and Taketomi, Akinobu},
  title = {Prognostic significance of Albumin–Bilirubin score changes in patients treated with systemic therapy for recurrent hepatocellular carcinoma after liver resection},
  journal = {Surgery Today},
  year = {2025},
  doi = {10.1007/s00595-025-03217-5}
}
Kostenlos starten →